High Frequency of Potential Phosphodiesterase Type 5 Inhibitor Drug Interactions in Males with HIV Infection and Erectile Dysfunction

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 May 6

PMID 33956843

Citations 1

Authors

Jason M Cota

Taylor M Benavides

John D Fields

Nathan Jansen

Anuradha Ganesan

Rhonda E Colombo

Jason M Blaylock

Ryan C Maves

Brian K Agan

Jason F Okulicz

Affiliations

Soon will be listed here.

Abstract

Objectives: We sought to determine the prevalence of phosphodiesterase type 5 inhibitor (PDE-5) mediated drug-drug interactions (DDIs) in males with HIV infection receiving antiretroviral therapy (ART) and identify factors associated with PDE-5-mediated DDIs.

Methods: Male US Military HIV Natural History Study participants diagnosed with erectile dysfunction (ED) and having a PDE-5 inhibitor and potentially-interacting ART co-dispensed within 30 days were included. DDIs were defined according to criteria found in published guidelines and drug information resources. The primary outcome of interest was overall PDE-5 inhibitor-mediated DDI prevalence and episode duration. A secondary logistic regression analysis was performed on those with and without DDIs to identify factors associated with initial DDI episode.

Results: A total of 235 male participants with ED met inclusion criteria. The majority were White (50.6%) or African American (40.4%). Median age at medication co-dispensing (45 years), duration of HIV infection (14 years), and duration of ED (1 year) did not differ between the two groups (p>0.05 for all). PDE-5 inhibitors included sildenafil (n = 124), vardenafil (n = 99), and tadalafil (n = 14). ART regimens included RTV-boosted protease inhibitors (PIs) atazanavir (n = 83) or darunavir (n = 34), and COBI-boosted elvitegravir (n = 43). Potential DDIs occurred in 181 (77.0%) participants, of whom 122 (67.4%) had multiple DDI episodes. The median DDI duration was 8 (IQR 1-12) months. In multivariate analyses, non-statistically significant higher odds of DDIs were observed with RTV-boosted PIs or PI-based ART (OR 2.13, 95% CI 0.85-5.37) and in those with a diagnosis of major depressive disorder (OR 1.74, 95% CI 0.83-3.64).

Conclusions: PDE-5-mediated DDIs were observed in the majority of males with HIV infection on RTV- or COBI-boosted ART in our cohort. This study highlights the importance of assessing for DDIs among individuals on ART, especially those on boosted regimens.

Citing Articles

Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus.

Dickstein D, Edwards C, Rowan C, Avanessian B, Chubak B, Wheldon C Nat Rev Gastroenterol Hepatol. 2024; 21(6):377-405.

PMID: 38763974 DOI: 10.1038/s41575-024-00932-1.

References

Colebunders R, Smets E, Verdonck K, Dreezen C . Sexual dysfunction with protease inhibitors. Lancet. 1999; 353(9166):1802. DOI: 10.1016/S0140-6736(05)75908-0. View

Smith J, Caan B, Sternfeld B, Haque R, Quesenberry Jr C, Quinn V . Racial disparities in erectile dysfunction among participants in the California Men's Health Study. J Sex Med. 2009; 6(12):3433-9. DOI: 10.1111/j.1743-6109.2009.01519.x. View

Sangiovanni R, Jakeman B, Nasiri M, Ruth L, Mahatme S, Patel N . Short Communication: Relationship Between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations Among Patients Living with HIV Initiating Combination Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2019; 35(5):430-433. PMC: 6508060. DOI: 10.1089/AID.2018.0205. View

Kobayashi M, Takata Y, Goseki Y, Mizukami H, Hara S, Kuriiwa F . A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2014; 179:421-3. DOI: 10.1016/j.ijcard.2014.11.090. View

Hall M, Ahmad S . Interaction between sildenafil and HIV-1 combination therapy. Lancet. 1999; 353(9169):2071-2. DOI: 10.1016/S0140-6736(05)77889-2. View

Iniesta-Navalon C, Franco-Miguel J, Gascon-Canovas J, Rentero-Redondo L . Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach. HIV Med. 2014; 16(5):273-9. DOI: 10.1111/hiv.12205. View

Nandwani R, Gourlay Y . Possible interaction between sildenafil and HIV combination therapy. Lancet. 1999; 353(9155):840. DOI: 10.1016/S0140-6736(99)90041-7. View

Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016; 17 Suppl 4:s2-s104. DOI: 10.1111/hiv.12426. View

Merry C, Barry M, Ryan M, Tjia J, Hennessy M, Eagling V . Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999; 13(15):F101-7. DOI: 10.1097/00002030-199910220-00001. View

10.

Fumaz C, Ayestaran A, Perez-Alvarez N, Munoz-Moreno J, Ferrer M, Negredo E . Clinical and Emotional Factors Related to Erectile Dysfunction in HIV-Infected Men. Am J Mens Health. 2016; 11(3):647-653. PMC: 5675217. DOI: 10.1177/1557988316669041. View

11.

Patel N, Abdelsayed S, Veve M, Miller C . Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011; 45(3):317-24. DOI: 10.1345/aph.1P576. View

12.

Demessine L, Peyro-Saint-Paul L, Gardner E, Ghosn J, Parienti J . Risk and Cost Associated With Drug-Drug Interactions Among Aging HIV Patients Receiving Combined Antiretroviral Therapy in France. Open Forum Infect Dis. 2019; 6(3):ofz051. PMC: 6440683. DOI: 10.1093/ofid/ofz051. View

13.

Santi D, Brigante G, Zona S, Guaraldi G, Rochira V . Male sexual dysfunction and HIV--a clinical perspective. Nat Rev Urol. 2014; 11(2):99-109. DOI: 10.1038/nrurol.2013.314. View

14.

Yiu P, Nguyen N, Holodniy M . Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy. 2011; 31(5):480-9. DOI: 10.1592/phco.31.5.480. View

15.

Sekar V, Lefebvre E, De Marez T, De Pauw M, De Paepe E, Vangeneugden T . Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig. 2008; 28(8):479-85. DOI: 10.2165/00044011-200828080-00002. View

16.

Miller C, El-Kholi R, Faragon J, Lodise T . Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy. 2007; 27(10):1379-86. DOI: 10.1592/phco.27.10.1379. View

17.

Pecora Fulco P, Patel B . Sildenafil Use for Pulmonary Artery Hypertension With a Cobicistat-Boosted Antiretroviral Regimen. Ann Pharmacother. 2019; 54(1):84-85. DOI: 10.1177/1060028019865542. View

18.

Luo L, Deng T, Zhao S, Li E, Liu L, Li F . Association Between HIV Infection and Prevalence of Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017; 14(9):1125-1132. DOI: 10.1016/j.jsxm.2017.07.001. View

19.

Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, Patel N . Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Ann Pharmacother. 2017; 51(5):365-372. DOI: 10.1177/1060028016685115. View

20.

Muirhead G, Wulff M, Fielding A, Kleinermans D, Buss N . Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000; 50(2):99-107. PMC: 2014393. DOI: 10.1046/j.1365-2125.2000.00245.x. View